Q3 2024 13F Holders as of 30 Sep 2024
-
Type / Class
-
Equity / Ordinary shares, $0.50 nominal value per share (the "Ordinary Shares")
-
Shares outstanding
-
125,610,040
-
Total 13F shares
-
71,540,427
-
Share change
-
+8,225,421
-
Total reported value
-
$699,253,141
-
Put/Call ratio
-
81%
-
Price per share
-
$9.75
-
Number of holders
-
100
-
Value change
-
+$54,237,351
-
Number of buys
-
53
-
Number of sells
-
50
Institutional Holders of Indivior Pharmaceuticals, Inc. - Ordinary shares, $0.50 nominal value per share (the "Ordinary Shares") (INDV) as of Q3 2024
As of 30 Sep 2024,
Indivior Pharmaceuticals, Inc. - Ordinary shares, $0.50 nominal value per share (the "Ordinary Shares") (INDV) was held by
100 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
71,540,427 shares.
The largest 10 holders included
Two Seas Capital LP, OAKTREE CAPITAL MANAGEMENT LP, MORGAN STANLEY, DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C), GOLDMAN SACHS GROUP INC, VANGUARD GROUP INC, Madison Avenue Partners, LP, NORGES BANK, BARCLAYS PLC, and BANK OF AMERICA CORP /DE/.
This page lists
100
institutional shareholders reporting positions in this security
for the Q3 2024 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.